In contrast, the sensitivities of methylated KCNQ5 for AA and SP, 75.0 and 36.6%, appeared significantly higher than those of Cologuard, suggesting a better performance in a screening setting where identification of precancerous lesions and early stage CRC was preferred. This evidence concerns the gene KCNQ5 and colorectal carcinoma.